Cerecor Inc (CERC)

2.93  -0.05 (-1.68%)

After market: 2.9468 +0.02 (+0.57%)

Fundamental Rating

2

Taking everything into account, CERC scores 2 out of 10 in our fundamental rating. CERC was compared to 198 industry peers in the Pharmaceuticals industry. CERC may be in some trouble as it scores bad on both profitability and health. CERC does not seem to be growing, but still is valued expensively.



0

1. Profitability

1.1 Basic Checks

CERC had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -119.98%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -1201.64%
PM (TTM) -1194.83%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

3

2. Health

2.1 Basic Checks

CERC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -4.37, we must say that CERC is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 0.79 indicates that CERC is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z -4.37
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 2.19 indicates that CERC has no problem at all paying its short term obligations.
A Quick Ratio of 2.18 indicates that CERC has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 2.18

3

3. Growth

3.1 Past

CERC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -49.12%.
CERC shows a decrease in Revenue. In the last year, the revenue decreased by -6.39%.
Measured over the past years, CERC shows a very negative growth in Revenue. The Revenue has been decreasing by -37.78% on average per year.
EPS 1Y (TTM)-49.12%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q5.26%
Revenue 1Y (TTM)-6.39%
Revenue growth 3Y-37.78%
Revenue growth 5YN/A
Revenue growth Q2Q150.78%

3.2 Future

CERC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.94% yearly.
The Revenue is expected to grow by 120.79% on average over the next years. This is a very strong growth
EPS Next Y4.09%
EPS Next 2Y11.13%
EPS Next 3Y16.75%
EPS Next 5Y7.94%
Revenue Next Year-12.27%
Revenue Next 2Y17.22%
Revenue Next 3Y104.26%
Revenue Next 5Y120.79%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

0

4. Valuation

4.1 Price/Earnings Ratio

CERC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CERC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -3.42

4.3 Compensation for Growth

A more expensive valuation may be justified as CERC's earnings are expected to grow with 16.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.13%
EPS Next 3Y16.75%

0

5. Dividend

5.1 Amount

No dividends for CERC!.
Industry RankSector Rank
Dividend Yield N/A

Cerecor Inc

NASDAQ:CERC (8/25/2021, 7:25:06 PM)

After market: 2.9468 +0.02 (+0.57%)

2.93

-0.05 (-1.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap281.31M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -119.98%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -1201.64%
PM (TTM) -1194.83%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.19
Quick Ratio 2.18
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-49.12%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y4.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-6.39%
Revenue growth 3Y-37.78%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y